occurs in has participant quality has disease treated with drug occurs in patient having disease occurs in patient treated with drug Propafenone [Chemical/Ingredient] VENLAFAXINE VINORELBINE TOPOTECAN ROPINIROLE HYDROXYUREA INDOMETHACIN AMIODARONE HYDROCHLORIDE CYTARABINE CYCLOSPORINE LEUPROLIDE ACETATE MITOXANTRONE HYDROCHLORIDE CLOMIPRAMINE DILTIAZEM DOXORUBICIN PERGOLIDE SIMVASTATIN PAROXETINE LANSOPRAZOLE BICALUTAMIDE LEVOFLOXACIN TOLCAPONE CAPECITABINE RABEPRAZOLE ALOSETRON LINEZOLID IMATINIB VALGANCICLOVIR BORTEZOMIB MEMANTINE TINIDAZOLE ERLOTINIB LENALIDOMIDE NELARABINE NILOTINIB CABAZITAXEL ERIBULIN CRIZOTINIB secondary progressive multiple sclerosis Cytomegalovirus retinitis heart conduction disease prostate cancer prostate carcinoma hypertension obsessive-compulsive disorder lymphocytic choriomeningitis dementia generalized anxiety disorder Parkinson's disease major depressive disorder breast cancer cancer duodenal ulcer pancreatic cancer anxiety disorder colon cancer ovarian cancer endometriosis non-small cell lung carcinoma pneumonia acute T cell leukemia congestive heart failure rheumatoid arthritis gastroesophageal reflux disease chronic myeloid leukemia bacterial pneumonia acute myeloid leukemia amebiasis colorectal cancer multiple myeloma irritable bowel syndrome hypereosinophilic syndrome Elderly Child Adult Adolescent constipation AE 10010774 infrequent bowel movements AE CTCAE: E10562 MP: MP_0003267 According to the Vaccine Adverse Event Reporting System (VAERS), 'constipation'; is an adverse event that was mentioned in 242 VAERS reports (0.2%) during1991-2001 (Reference: PMID: 12825543). SIDER: C0009806 NCIt: C37930 HPO: HP_0002019 an abnormal defecation AE that has an outcome of constipation, which is incomplete, infrequent or difficult evacuation of fecal matter abnormal defecation AE AE severity G1 AE severity G2 AE severity G3 AE severity G4 AE severity G5